Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

Subjects: patients with postoperative local recurrent or metastatic differentiated thyroid cancer . Experimental group: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days. Control group: Thyroid hormone withdraw for 4-6 weeks. The two groups were treated with radioiodine 131I after plasma thyroid stimulating hormone elevated (\>30mU/L). The efficacy and adverse reactions were observed.

Trial Details

NCT ID
NCT06405217
Phase
NA
Sponsor
Nanjing First Hospital, Nanjing Medical University
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Recombinant Human Thyroid Stimulating Hormone
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Age: 18\~75 years old (including 18 and 75 years old);
  • ECOG: 0-2 points;
  • Expected survival of more than 3 months; Differentiated thyroid carcinoma undergoing total thyroidectomy or subtotal thyroidectomy and confirmed as…
  • Hemoglobin ≥80g/L, neutrophil ≥1.5×109/L, platelet count ≥80×109/L, serum creatinine ≤1.5× upper limit of normal or creatinine clearance ≥60ml/min,…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →